[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350069-105":59,"doc-detail-350069-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","clinical-validation-of-digital-pcrbased-ctdna-detection-for-risk-stratification-in-residual-triple-negative-breast-cancer-tricia-trial-results","Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer - TRICIA Trial Results","","Triple-negative breast cancer patients with residual tumor after neoadjuvant chemotherapy have poor outcomes, and identifying who benefits from adjuvant capecitabine remains critical. The TRICIA trial measured a tumor-informed digital droplet PCR ctDNA assay across plasma sampling before and after surgery and during adjuvant therapy in non-pCR patients, using a median 38-month follow-up. ctDNA detection before clinical relapse was frequent, and absence at the post-NAC/preoperative time point strongly predicted distant relapse-free survival. Detection aligned with residual cancer burden risk, and capecitabine was associated with ctDNA clearance linked to favorable prognosis.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-validation-of-digital-pcrbased-ctdna-detection-for-risk-stratification-in-residual-triple-negative-breast-cancer-tricia-trial-results/350069/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-validation-of-digital-pcrbased-ctdna-detection-for-risk-stratification-in-residual-triple-negative-breast-cancer-tricia-trial-results/350069.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical problem does the TRICIA study address?","Question",{"text":113,"@type":114},"TRICIA targets patients with triple-negative breast cancer who have residual tumor at surgery after neoadjuvant chemotherapy, a group with high relapse and death risk. The study evaluates how ctDNA testing can identify those who may benefit from additional adjuvant capecitabine therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was ctDNA measured and at what time points?",{"text":118,"@type":114},"Plasma was collected at multiple stages: before surgery and after NAC (T1), after surgery (T2), during adjuvant capecitabine (T3), and late after surgery after completion of adjuvant treatment (T4). A tumor-informed digital droplet PCR assay quantified ctDNA.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings for prognosis and residual disease risk?",{"text":122,"@type":114},"ctDNA was detected in most patients before clinical relapse, and lack of detection at T1 was highly prognostic for distant-disease relapse-free survival. ctDNA detection also correlated with residual cancer burden, with reported high sensitivity and specificity for RCB 3 patients.",{"name":124,"@type":111,"acceptedAnswer":125},"How did capecitabine relate to ctDNA dynamics and outcomes?",{"text":126,"@type":114},"During capecitabine therapy, ctDNA clearance occurred in a substantial proportion of cases. The study reports that clearance was associated with a good prognosis, supporting ctDNA as a monitoring signal during treatment.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},350069,1790134832,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":36,"preview_page_count":19,"preview_urls":150},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results  \nTalia Roseshter1,2, Anna Klemantovich2, Josiane Lafleur2, Cathy Lan2, Luca Cavallone2, Kathryn Bozek1,2, Juliet Guay1,2, Oluwadara Elebute3, Sarah Jenna3, Rodney Ouellette4, Suzan McNamara5, Jean-Francois Boileau2,6,7, Manuela Pelmus8, Muriel Brackstone9, Rossanna Pezo10, Terry Ng11, Adriana Aguilar-Mahecha2, and Mark Basik1,2,6,7  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Patients with triple-negative breast cancer (TNBC) who have residual tumor at surgery [nonpathologic complete response or (non-pCR)] after neoadjuvant chemotherapy (NAC) have a poor prognosis. In these cases, adjuvant ch∼ emotherapy with\u003Cbr>capecitabine improves disease-free survival in 15% of patients. Identifying those who would benefit from such additional therapy remains a critical need.\u003Cbr>Experimental Design: In the TRICIA trial, 92 patients with non-pCR provided plasma before surgery and after NAC (T1), after surgery (T2), during adjuvant capecitabine therapy (T3), and late after surgery following completion of adjuvant treatment (T4) . The sensitivity, specificity, and predictive values of a tumor-informed digital droplet–based ctDNA detection assay were measured with a median follow-up of 38 months.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: ctDNA was detected in 97% of patients before clinical relapse. We confirmed that the lack of detection of ctDNA at the post-NAC/preoperative (T1) time point is highly prognostic, with 95% distant-disease relapse-free survival. The detection of ctDNA inpatients with significant residual tumor (Residual Cancer Burden 2/3) was also highly prognostic and our test performed with 100% sensitivity and 100% specificity in RCB 3 patients. We measured three time points before, during, and after capecitabine treatment and found that capecitabine treatment was associated with clearance of ctDNA in 41% of cases, and clearance was associated with good prognosis.\u003Cbr>Conclusions: These findings suggest that ctDNA testing using digital droplet PCR assays in an academic hospital-based context can reliably identify a very low-risk group of patients with nonpCR TNBC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTriple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and accounts for about 15% to 20% of all breast cancers (1). The term “triple negative” refers to the lack of protein expression of the three most common biomarkers in the treatment of breast cancer: estrogen receptors, progesterone receptors, and HER2. The lack of these receptors makes TNBC unresponsive to common hormonal therapies or  \n1Department of Clinical and Translational Research, McGill University, Montreal, Canada. 2Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montrea","cbCaij7PYOWFDT8p","https://ap.wps.com/l/cbCaij7PYOWFDT8p","pdf",5016439,16,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What clinical problem does the TRICIA study address?\",\"answer\":\"TRICIA targets patients with triple-negative breast cancer who have residual tumor at surgery after neoadjuvant chemotherapy, a group with high relapse and death risk. The study evaluates how ctDNA testing can identify those who may benefit from additional adjuvant capecitabine therapy.\"},{\"question\":\"How was ctDNA measured and at what time points?\",\"answer\":\"Plasma was collected at multiple stages: before surgery and after NAC (T1), after surgery (T2), during adjuvant capecitabine (T3), and late after surgery after completion of adjuvant treatment (T4). A tumor-informed digital droplet PCR assay quantified ctDNA.\"},{\"question\":\"What were the key findings for prognosis and residual disease risk?\",\"answer\":\"ctDNA was detected in most patients before clinical relapse, and lack of detection at T1 was highly prognostic for distant-disease relapse-free survival. ctDNA detection also correlated with residual cancer burden, with reported high sensitivity and specificity for RCB 3 patients.\"},{\"question\":\"How did capecitabine relate to ctDNA dynamics and outcomes?\",\"answer\":\"During capecitabine therapy, ctDNA clearance occurred in a substantial proportion of cases. The study reports that clearance was associated with a good prognosis, supporting ctDNA as a monitoring signal during treatment.\"}]","Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer - TRICIA Trial Results | PDF",1790086988,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e73667ae82b06751f8c9e335211ba7d7.webp",983,1315,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a23a2c9c1aeeb709180cd85d20adf43c.webp",982,1314,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30d97a33c4a7cd5a708208dbba4d7f36.webp",981,1312,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/783ace5f479e9709df197950d2a6e457.webp",980,1311]